Watching a psoriasis commercial advertising psoriasis treatment plans is heartbreaking, especially when you have experienced the pain and swelling of psoriasis lesions and understand how hard it is to alleviate the symptoms. Advertisements promoting psoriasis medications usually involve only well-known and frequently prescribed drugs, such as Humira, Dovonex and Stelara, three drugs known for their successfulness in treating psoriasis plaques.
While a commercial may introduce you to certain psoriasis treatments, details about the medication are incomplete due to time constraints. The next time you view a psoriasis commercial, keep in mind it is only part of the whole story.
Humira is meant for grownups with modest to extreme psoriasis along with psoriatic joint inflammation that have trouble regulating episodes. Clinically described as a TNF, or lump death element medicine, Humira enhances the body's inflammatory feedback to neutralize psoriasis along with various other problems such as Crohn's illness, ankylosing spondylitis, rheumatoid joint inflammation and also some kinds of bronchial asthma.
While Humira benefits many psoriasis sufferers, it does carry the risk of side effects that are potentially serious. People taking Humira or any other TNF alpha-blocker should immediately report adverse conditions such as:
In rare cases, Humira may cause worsening of psoriasis symptoms involving pus-filled bumps in addition to the usual scaly, painful lesions.
A Humira psoriasis commercial may not inform users that TNF blockers raise the risk of developing lymphoma and certain other cancers in both adults and children. I
nstances of a rare form of cancer called hepatosplenic T-cell lymphoma have occurred as a consequence of taking Humira in certain individuals sensitive to the effects of TNF blockers. Because Humira is injected, site irritations may occur that include redness, soreness and swelling.
Dovonex is a calcipotriene ointment for topical use only that contains a synthetic derivative of vitamin D called calcipotriene. Side effects associated with Dovonex ointment are extremely rare, with allergic reactions being the most common. Initial burning and excessive dryness may occur but usually lessen as treatment continues.
Controlled trials with Dovonex have shown that after two weeks of using this medication, patients experience visible improvement with psoriasis lesions. After two months, nearly 60 percent of patients showed marked improvements, with 7 percent demonstrating complete remission of their psoriasis.
People using Dovonex should inform the physician prescribing the medication if they have hypercalcemia, or high vitamin D and/or calcium levels. Additionally, this ointment may make some individuals more sensitive to sunlight. Product instructions advise patients to avoid tanning beds and extended exposure to the sun.
A psoriasis commercial about Stelara will reveal the following:
When watching a psoriasis commercial advertising medications not discussed here, pay attention to risks involved as well as method of application and any other warnings pertinent to your health situation. Also keep in mind, a healthier alternative natural treatment might be available as well.